^
    1year
    Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors. (ASCO 2023)
    GEC255 has been well tolerated at the doses tested and has shown encouraging anticancer activity to advanced NSCLC patients with KRASG12C mutation pts. MTD has not been determined, and enrollment into the dose exploration is ongoing. (http://www.chinadrugtrials.org.cn/index.html).
    Clinical • P1 data • PK/PD data • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    GEC-255
    1year
    Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (clinicaltrials.gov)
    P1, N=70, Recruiting, GenEros Biopharma Hangzhou Ltd
    New P1 trial • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    GEC-255